Company profile: Thrombolex
1.1 - Company Overview
Company description
- Provider of innovative endovascular catheters, designing, developing, manufacturing, and distributing devices for arterial and venous thromboembolic conditions using mechanical and pharmacological methods. Offerings include BASHIR Endovascular Catheters, BASHIR Plus with an expandable infusion basket for extensive thrombus in peripheral vessels, and BASHIR S-B for shorter peripheral and pulmonary vessels.
Products and services
- BASHIR™ Plus Endovascular Catheter: Interventional-grade device for peripheral vessels with extensive thrombus burden, delivering thrombolytics via an expandable infusion basket and along a segment of the distal catheter shaft
- BASHIR™ Endovascular Catheters: Custom-engineered family for arterial and venous thromboembolic conditions, utilizing a combination of mechanical and pharmacological methods to restore blood flow within affected vessels
- BASHIR™ S-B Endovascular Catheter: Precision-focused model for shorter peripheral and pulmonary vessels, featuring a shorter expandable infusion basket enabling controlled and selective infusion of fluids.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Thrombolex
Instylla
HQ: United States
Website
- Description: Provider of next-generation liquid embolics for interventional radiology. Offers the Embrace Hydrogel Embolic System (HES), a device that embolizes hypervascular tumors and peripheral arterial bleeds by forming a soft hydrogel to fill vessel lumens during embolization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Instylla company profile →
Direct Flow Medical
HQ: United States
Website
- Description: Provider of medical implants used in the treatment of aortic and heart valve diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Direct Flow Medical company profile →
HeartSciences
HQ: United States
Website
- Description: Provider of AI-based ECG technology, offering the MyoVista wavECG Device, a 12-lead resting electrocardiograph using wavelet signal processing and AI to detect cardiac dysfunction, including LV relaxation abnormalities; the MyoVista Energy Waveform, for visual context and assessing signal quality issues (not for clinical assessment); and the MyoVista wavECG LV Relaxation Algorithm indicating levels of LV relaxation abnormality.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HeartSciences company profile →
HeartHero
HQ: United States
Website
- Description: Provider of portable automated external defibrillator technology and companion mobile app. HeartHero's Elliot AED is designed for non-medical users and offers audio/visual prompts, multilingual support, and connectivity for remote monitoring and post-event data access. The HeartHero App connects to the AED to monitor device status, manage settings, access training videos, and order replacement supplies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HeartHero company profile →
NovaCardia
HQ: United States
Website
- Description: Provider of cardiovascular drug development and commercialization of novel small molecule drugs to improve care for patients with cardiovascular disease; a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NovaCardia company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Thrombolex
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Thrombolex
2.2 - Growth funds investing in similar companies to Thrombolex
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Thrombolex
4.2 - Public trading comparable groups for Thrombolex
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →